Dana T. Aftab

3.6k total citations
45 papers, 1.8k citations indexed

About

Dana T. Aftab is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Dana T. Aftab has authored 45 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 17 papers in Molecular Biology. Recurrent topics in Dana T. Aftab's work include Pancreatic and Hepatic Oncology Research (10 papers), Prostate Cancer Treatment and Research (9 papers) and Renal cell carcinoma treatment (6 papers). Dana T. Aftab is often cited by papers focused on Pancreatic and Hepatic Oncology Research (10 papers), Prostate Cancer Treatment and Research (9 papers) and Renal cell carcinoma treatment (6 papers). Dana T. Aftab collaborates with scholars based in United States, France and Canada. Dana T. Aftab's co-authors include Donald M. McDonald, Barbara Sennino, Weon‐Kyoo You, Casey W. Williamson, William N. Hait, Renee N. Donahue, Andressa Ardiani, James W. Hodge, Anna Kwilas and Sébastien P. Tabruyn and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Dana T. Aftab

44 papers receiving 1.8k citations

Peers

Countries citing papers authored by Dana T. Aftab

Since Specialization

Citations

This map shows the geographic impact of Dana T. Aftab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana T. Aftab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana T. Aftab more than expected).

Fields of papers citing papers by Dana T. Aftab

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dana T. Aftab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana T. Aftab. The network helps show where Dana T. Aftab may publish in the future.

Co-authorship network of co-authors of Dana T. Aftab

This figure shows the co-authorship network connecting the top 25 collaborators of Dana T. Aftab. A scholar is included among the top collaborators of Dana T. Aftab based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dana T. Aftab. Dana T. Aftab is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	831 AXL Receptor Tyrosine Kinase Expression in Metastatic Renal Cell Carcinoma: Insights from the METEOR trial 2025 ·Laboratory Investigation ·(unknown), Paul Morgan, (unknown), (unknown), (unknown), (unknown), (unknown), Thomas Denize, (unknown), (unknown), (unknown), Sachet A. Shukla, David Braun, (unknown), Dana T. Aftab, Eddy Saad, (unknown), Wanling Xie, Toni K. Choueiri, Sabina Signoretti	1
2	Expression of the receptor tyrosine kinase AXL and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma enrolled in the METEOR trial. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), Thomas Denize, (unknown), (unknown), (unknown), Maxine Sun, Renée Maria Saliby, Eddy Saad, (unknown), David A. Braun, Dana T. Aftab, Wanling Xie, Toni K. Choueiri, Sabina Signoretti	2
3	Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma 2023 ·Clinical Cancer Research ·Benjamin M. Ellingson, Akifumi Hagiwara, (unknown), Nicholas S. Cho, (unknown), Francesco Sanvito, Talia C. Oughourlian, Donatello Telesca, Catalina Raymond, Lauren E. Abrey, Josep Garcia, Dana T. Aftab, Colin Hessel, (unknown), Dror Harats, David A. Nathanson, Patrick Y. Wen, Timothy F. Cloughesy	5
4	Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma 2021 ·BMC Cancer ·Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta K. Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn N. Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George	12
5	Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer. 2019 ·Journal of Clinical Oncology ·Howard I. Scher, Robert McCormack, Arturo Molina, Matthew R. Smith, Robert Dreicer, Fred Saad, Ronald de Wit, Karim Fizazi, Dana T. Aftab, (unknown), Martin Fleisher, Johann S. de Bono, Gary J. Kelloff, Glenn Heller	1
6	Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–small-cell Lung Carcinoma 2018 ·Clinical Lung Cancer ·Beth A. Hellerstedt, Nicholas J. Vogelzang, Harriet M. Kluger, Christopher A. Yasenchak, Dana T. Aftab, David A. Ramies, Michael S. Gordon, Primo Lara	18
7	Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations 2016 ·Molecular Cancer Therapeutics ·Yemarshet K. Gebreyohannes, Patrick Schöffski, Thomas Van Looy, Jasmien Wellens, (unknown), Jasmien Cornillie, Ulla Vanleeuw, Dana T. Aftab, Maria Dêbiec‐Rychter, Raf Sciot, Agnieszka Woźniak	29
8	Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials 2016 ·Neuro-Oncology ·Benjamin M. Ellingson, Robert J. Harris, Davis C. Woodworth, Kevin Leu, (unknown), Warren Mason, Solmaz Sahebjam, Lauren E. Abrey, Dana T. Aftab, Gisela Schwab, Colin Hessel, Albert Lai, Phioanh L. Nghiemphu, Whitney B. Pope, Patrick Y. Wen, Timothy F. Cloughesy	55
9	Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer 2016 ·Cancer ·Steven I. Sherman, Douglas O. Clary, Rossella Elisei, Martin Schlumberger, Ezra E.W. Cohen, Patrick Schöffski, Lori J. Wirth, Milan Mangeshkar, Dana T. Aftab, Marcia S. Brose	70
10	Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites 2015 ·Drug Metabolism and Disposition ·Steven Lacy, (unknown), Dale Miles, Dana T. Aftab, Ronghua Wang, Linh T. Nguyen	66
11	Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine 2014 ·Journal of Translational Medicine ·Anna Kwilas, Andressa Ardiani, Renee N. Donahue, Dana T. Aftab, James W. Hodge	154
12	Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions 2013 ·Clinical Cancer Research ·Jinlu Dai, Honglai Zhang, (unknown), Jill M. Keller, Kenneth M. Kozloff, Dana T. Aftab, Frauke Schimmöller, Evan T. Keller	79
13	Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors 2012 ·Cancer Discovery ·Barbara Sennino, Toshina Ishiguro‐Oonuma, Ying Wei, Ryan M. Naylor, Casey W. Williamson, Vikash Bhagwandin, Sébastien P. Tabruyn, Weon‐Kyoo You, Harold A. Chapman, James G. Christensen, Dana T. Aftab, Donald M. McDonald	325
14	VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer 2011 ·Cancer Research ·Weon‐Kyoo You, Barbara Sennino, Casey W. Williamson, Beverly L. Falcón, Hiroya Hashizume, Li‐Chin Yao, Dana T. Aftab, Donald M. McDonald	196
15	MET and VEGF: synergistic targets in castration-resistant prostate cancer 2011 ·Clinical & Translational Oncology ·Dana T. Aftab, Donald M. McDonald	36
16	EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib 2011 ·Journal of Thoracic Oncology ·Juliann Chmielecki, M. Catherine Pietanza, Dana T. Aftab, Ronglai Shen, Zhiguo Zhao, Xi Chen, Katherine E. Hutchinson, Agnès Viale, Mark G. Kris, Thomas J. Stout, Vincent A. Miller, Naiyer A. Rizvi, William Pao	17
17	Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide 2011 ·Neuro-Oncology ·Gautam Prasad, Theo Sottero, Xia Yang, Stefan C. Mueller, C. David James, William A. Weiss, (unknown), T. Ozawa, Mitchel S. Berger, Dana T. Aftab, Michael D. Prados, Daphne A. Haas‐Kogan	133
18	Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance 1992 ·Biochemical Pharmacology ·William N. Hait, Dana T. Aftab	68
19	Structure-Activity Relationships of Phenothiazines and Related Drugs for Inhibition of Protein Kinase C 1991 ·Molecular Pharmacology ·Dana T. Aftab, Lawrence M. Ballas, Carson R. Loomis, W N Hait	27
20	A semiautomated 96-well plate assay for protein kinase C 1990 ·Analytical Biochemistry ·Dana T. Aftab, William N. Hait	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact